Arena Pharmaceuticals, Inc. (ARNA)
-NasdaqGS 7.98 
0.02(0.25%) 18 May 04:00 SGT|After Hours
:
8.00 0.02 (0.25%) 18 May 07:57 SGT
| Prev Close: | 8.00 |
|---|
| Open: | 8.04 |
|---|
| Bid: | 7.80 x 5000 |
|---|
| Ask: | 8.63 x 1000 |
|---|
| 1y Target Est: | 8.36 |
|---|
| Beta: | -0.54 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | 7.94 - 8.06 |
|---|
| 52wk Range: | 5.50 - 13.50 |
|---|
| Volume: | 2,395,561 |
|---|
| Avg Vol (3m): | 5,355,570 |
|---|
| Market Cap: | 1.74B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.37 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Vivus Taps Into More Cashat Seeking Alpha(Sun, 19 May)
- 25 Belt-Busting Obesity Factsat Motley Fool(Sat, 18 May)
- Nasdaq stocks posting largest percentage decreasesAP(Sat, 18 May)
- ARENA PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Sat, 18 May)
- Arena Outlines Belviq Launch And Goalsat Seeking Alpha(Fri, 17 May)
- Weight Loss Isn't Just for Looking Good Anymoreat Motley Fool(Thu, 16 May)
- Vivus - Mild Drama Continuesat Seeking Alpha(Wed, 15 May)
- Will Obesity Drugs Gain Soon?at Motley Fool(Wed, 15 May)
- Ahead of the Bell: Arena Pharma price targets fallAP(Fri, 3 May)
- Arena shares plunge after disappointing 1Q resultsAP(Fri, 3 May)
- Vivus Unveils Qsymia Study ResultsZacks(Fri, 8 Feb)
- Update on Orexigen's ContraveZacks(Fri, 11 Jan)
- Takeda Terminates Amylin AgreementZacks(Mon, 31 Dec)
- Arena Cuts Loss, Affirms Sales ViewZacks(Fri, 9 Nov)
- Vivus Misses 3Q EstimatesZacks(Fri, 9 Nov)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 62.74 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.14 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.12 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | -2.29 |
|---|
Business Summary
Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory,...
View More